Oncotarget

Research Papers:

Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity

Amy J.C. Dohmen, Xiaohang Qiao, Anja Duursma, Ruud H. Wijdeven, Cor Lieftink, Floor Hageman, Ben Morris, Pasi Halonen, Conchita Vens, Michiel W.M. van den Brekel, Huib Ovaa, Jacques Neefjes and Charlotte L. Zuur _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:73925-73937. https://doi.org/10.18632/oncotarget.18034

Metrics: PDF 1112 views  |   HTML 2110 views  |   ?  


Abstract

Amy J.C. Dohmen1, Xiaohang Qiao2, Anja Duursma2, Ruud H. Wijdeven2, Cor Lieftink3, Floor Hageman4, Ben Morris3, Pasi Halonen3, Conchita Vens4, Michiel W.M. van den Brekel1,5, Huib Ovaa6,7, Jacques Neefjes6,7 and Charlotte L. Zuur1,5

1Department of Head and Neck Oncology and Surgery, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

2Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

3NKI Robotics and Screening Center, The Netherlands Cancer Institute, Amsterdam, The Netherlands

4Division of Biological Stress Response, The Netherlands Cancer Institute, Amsterdam, The Netherlands

5Department of Oral and Maxillofacial Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

6Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

7Department of Chemical Immunology, Leiden University Medical Center, Leiden, The Netherlands

Correspondence to:

Charlotte L. Zuur, email: c.zuur@nki.nl

Keywords: cancer, radiotherapy, radiosensitizer, ATM, DNA damage response

Received: December 21, 2016     Accepted: April 26, 2017     Published: May 19, 2017

ABSTRACT

Treatment of advanced head and neck squamous cell carcinoma (HNSCC) is plagued by low survival and high recurrence rates, despite multimodal therapies. Presently, cisplatin or cetuximab is used in combination with radiotherapy which has resulted in minor survival benefits but increased severe toxicities relative to RT alone. This underscores the urgent need for improved tumor-specific radiosensitizers for better control with lower toxicities. In a small molecule screen targeting kinases, performed on three HNSCC cell lines, we identified GSK635416A as a novel radiosensitizer. The extent of radiosensitization by GSK635416A outperformed the radiosensitization observed with cisplatin and cetuximab in our models, while exhibiting virtually no cytotoxicity in the absence of radiation and in normal fibroblast cells. Radiation induced phosphorylation of ATM was inhibited by GSK635416A. GSK63541A increased DNA double strand breaks after radiation and GSK63541A mediated radiosensitization was lacking in ATM-mutated cells thereby further supporting the ATM inhibiting properties of GSK63541A. As a novel ATM inhibitor with highly selective radiosensitizing activity, GSK635416A holds promise as a lead in the development of drugs active in potentiating radiotherapy for HNSCC and other cancer types.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18034